You are here: Home: Audio Program Guide: BCU Think Tank 1 | 2006 Audio: BCU Think Tank 1 | 2006
 

 
  Go to Section 1
Go to Section 2
Go to Section 3
Go to Section 4
 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.


Section 1: Adjuvant Therapy for Patients with HER2- Positive Tumors
   Click here to download the entire section  
Track 1 Introduction
Track 2 Importance of waiting for definitive research data before utilizing an unproven treatment approach
Track 3 Acceptance of trastuzumab as adjuvant therapy in the United Kingdom
Track 4 Biologic rationale for topoisomerase II-alpha (TOPO II) amplification predicting sensitivity to anthracyclines
Track 5 TOPO II amplification and the efficacy of anthracycline-based chemotherapy in BCIRG 006
Track 6 Clinical use of TOPO II amplification to select adjuvant chemotherapy for patients with HER2-positive disease

Track 7 Lack of reliable HER2 testing in the United States
Track 8 Potential benefit of adjuvant trastuzumab monotherapy
Track 9 Concurrent versus sequential administration of trastuzumab and chemotherapy
Track 10 Sequential use of trastuzumab and cardiac toxicity
Track 11 Duration of adjuvant trastuzumab
Track 12 Necessity of clinical trials examining the duration of adjuvant trastuzumab
Track 13 Clinical use of adjuvant trastuzumab monotherapy
Track 14 Role of cardiac monitoring in treatment decisionmaking regarding adjuvant trastuzumab
Track 15 Use of Oncotype DX™ to determine therapy for patients with ER-positive, HER2-positive disease
Track 16 Quality control in ER and HER2 testing
Track 17 Efforts to improve national standards for ER and HER2 testing


Section 2: Adjuvant Chemotherapy
   Click here to download the entire section  
Track 1 Prophylactic growth factor support to prevent febrile neutropenia with adjuvant chemotherapy
Track 2 Clinical use of prophylactic growth factor support in the adjuvant setting
Track 3 Defining an acceptable level of risk for the development of neutropenia
Track 4 Use of docetaxel/cyclophosphamide versus AC in the adjuvant setting
Track 5 Clinical trial data examining the benefit of adjuvant chemotherapy for patients with ER-positive disease
Track 6 Adjuvant TAC versus dose-dense AC/paclitaxel for patients with ER-positive disease

Track 7 Quality control in hormone receptor testing
Track 8 BCIRG 005: Adjuvant TAC versus AC followed by docetaxel
Track 9 Amenorrhea with TAC versus AC/paclitaxel
Track 10 Benefit of adjuvant chemotherapy for patients with ER-positive disease
Track 11 ECOG-PACCT-1: Adjuvant hormonal therapy with or without chemotherapy based on the Oncotype DX recurrence score
Track 12 Benefit of chemotherapy in addition to hormonal therapy

 

Section 3: Adjuvant Endocrine Therapy for Patients with ER-Positive Tumors
   Click here to download the entire section  
Track 1 Optimal long-term treatment strategy for postmenopausal patients with ER-positive disease
Track 2 Side effects associated with aromatase inhibitors versus tamoxifen
Track 3 Rationale for use of an up-front aromatase inhibitor versus switching at two to three years
Track 4 Meta-analysis of adjuvant aromatase inhibitor trials
Track 5 Lack of long-term toxicity data with aromatase inhibitors
Track 6 Trials of up-front versus switching aromatase inhibitors

Track 7 Use of computer models to select optimal adjuvant hormonal therapy
Track 8 Potential benefit of sequencing an aromatase inhibitor after two to three years of tamoxifen
Track 9 Safety of long-term administration of aromatase inhibitors
Track 10 Duration of adjuvant hormonal therapy
Track 11 Sequencing tamoxifen after an aromatase inhibitor
Track 12 Role of HER2 and PR as predictive factors for tamoxifen responsiveness
Track 13 Effect of HER2 and PR status on response to aromatase inhibitors
Track 14 Clinical use of HER2 and PR to select adjuvant hormonal therapy
Track 15 Selection of optimal adjuvant hormonal therapy
Track 16 Adjuvant hormonal therapy for patients with low-risk disease
Track 17 Differential effects of hormonal therapies based on ER and PR status
Track 18 Selection of hormonal therapy for premenopausal women with ER-positive disease
Track 19 Aromatase inhibitors in combination with ovarian suppression for premenopausal patients
Track 20 Switching from tamoxifen to an aromatase inhibitor for premenopausal patients who become amenorrheic
Track 21 Clinical use of ovarian suppression and an aromatase inhibitor

 

Section 4: Systemic Management of Patients with Metastatic Disease
   Click here to download the entire section  
Track 1 Paclitaxel and bevacizumab for patients who have previously received adjuvant taxane therapy
Track 2 Potential benefit of combining bevacizumab and capecitabine
Track 3 Tolerability and efficacy of paclitaxel and bevacizumab as first-line therapy for metastatic disease
Track 4 Potential rationale for the slow incorporation of bevacizumab into clinical practice
Track 5 Weighing the costs of therapy versus the benefit to patients
Track 6 Rationale for using bevacizumab beyond the first-line setting

Track 7 Need for an ongoing dialogue about the rising cost of cancer treatment
Track 8 Trend for improvement in survival in ECOG-E2100
Track 9 Clinical use of bevacizumab in combination with capecitabine
Track 10 Continuation of bevacizumab after disease progression
Track 11 XCaliBr: Phase II study of capecitabine with bevacizumab followed by bevacizumab upon progression
Track 12 Mechanisms of resistance to anti-angiogenic therapy
Track 13 Importance of weighing overall societal costs versus the cost of an individual therapy
Track 14 Potential biologic rationale for benefit of adjuvant bevacizumab
Track 15 Evaluating the optimal duration of adjuvant bevacizumab
Track 16 Potential benefit of fulvestrant in combination with aromatase inhibitors
Track 17 Ovarian suppression and fulvestrant for premenopausal women
Track 18 Biologic rationale for using a loading dose of fulvestrant
Track 19 Sequencing hormonal therapy for premenopausal women with ER-positive metastatic disease
Track 20 Influence of aromatase inhibitors on intratumoral estrogen levels
Track 21 Incorporation of fulvestrant into the adjuvant setting
Track 22 Potential role of fulvestrant after five years of an aromatase inhibitor